'Breakthrough' mRNA cancer drug curbs melanoma in large trial

US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough." Researchers have for years been trying to apply mRNA treatments against cancer, but this was the first time such a drug showed positive results in a large, late-stage clinical trial.

By FRANCE24

CNA Explains: What we know about the Moderna, Merck breakthrough cancer vaccine

The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other cancers.